股本结构
单位：万股
| 公告日期 | 2025-11-14 | 2025-11-14 | 2023-11-13 | 2023-08-11 | 2022-03-31 | 2021-12-17 |
|---|---|---|---|---|---|---|
| 证券总股本 | 7194.88 | 6969.22 | 6588.09 | 6588.09 | 2881.53 | 2881.53 |
| 普通股本 | 7194.88 | 6969.22 | 6588.09 | 6588.09 | 2881.53 | 2881.53 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-11-10 | 2025-09-30 | 2023-09-30 | 2023-08-10 | 2021-12-31 | 2021-12-16 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-14 | 7194.88 | 未披露 | 定期报告 | 2025-11-10 |
| 2025-11-14 | 6969.22 | 未披露 |
更多>>
From January 1, 2025 to September 30, 2025
Issuance of common stock in connection with at-the-market program, net of issuance costs of $134
Issuance of common stock in connection with exercise of stock options
|
2025-09-30 |
| 2023-11-13 | 6588.09 | 未披露 |
更多>>
From January 1, 2023 to September 30, 2023
Issuance of common shares and warrants in private placement, net of issuance costs of $3,188
|
2023-09-30 |
| 2023-08-11 | 6588.09 | 未披露 | 定期报告 | 2023-08-10 |
| 2022-03-31 | 2881.53 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of class C preference shares, net of issuance costs of $340 and adjusted for settlement of tranche obligation of $28,276 of which $25,908 is non-cash
Exchange of preferred and ordinary shares of IO Biotech ApS into common stock of IO Biotech, Inc.
Issuance of common stock in connection with initial public offering, net of issuance costs of $11,765
|
2021-12-31 |
| 2021-12-17 | 2881.53 | 未披露 | 定期报告 | 2021-12-16 |
| 2021-11-08 | 2774.28 | 未披露 |
更多>>
1.Common stock offered 7,150,000 shares
2.The number of shares of common stock to be outstanding after the completion of this offering assumes that all of Class A stock is converted into 177,200 shares of common stock upon the closing of this offering, and all of outstanding convertible preferred stock is converted into 20,415,213 shares of common stock upon the closing of this offering, based on the initial public offering price of $14.00 per share, and is based on 354 shares of common stock outstanding as of October 15, 2021
|
2021-11-05 |
From January 1, 2025 to September 30, 2025
Issuance of common stock in connection with at-the-market program, net of issuance costs of $134
Issuance of common stock in connection with exercise of stock options
From January 1, 2023 to September 30, 2023
Issuance of common shares and warrants in private placement, net of issuance costs of $3,188
From December 31, 2020 to December 31, 2021
Issuance of class C preference shares, net of issuance costs of $340 and adjusted for settlement of tranche obligation of $28,276 of which $25,908 is non-cash
Exchange of preferred and ordinary shares of IO Biotech ApS into common stock of IO Biotech, Inc.
Issuance of common stock in connection with initial public offering, net of issuance costs of $11,765
1.Common stock offered 7,150,000 shares
2.The number of shares of common stock to be outstanding after the completion of this offering assumes that all of Class A stock is converted into 177,200 shares of common stock upon the closing of this offering, and all of outstanding convertible preferred stock is converted into 20,415,213 shares of common stock upon the closing of this offering, based on the initial public offering price of $14.00 per share, and is based on 354 shares of common stock outstanding as of October 15, 2021